NASDAQ: UTRSMinerva Surgical Inc Stock
$0.28-0.01 (-3.45%)
Updated Jun 5, 2023
UTRS Price
$0.28
Fair Value Price
N/A
Market Cap
$49.52M
52 Week Low
$0.15
52 Week High
$2.89
P/E
-0.3x
P/B
1.45x
P/S
0.41x
PEG
N/A
Dividend Yield
N/A
Revenue
$51.89M
Earnings
-$34.53M
Gross Margin
55.6%
Operating Margin
-59.47%
Profit Margin
-66.5%
Debt to Equity
1.5
Operating Cash Flow
-$36M
Beta
0.55
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
UTRS Overview
Minerva Surgical, Inc. manufactures minimally invasive uterine healthcare devices in the U.S. Offerings include the Minerva ES Endometrial Ablation and Genesys HTA Endometrial Ablation Systems, which are endometrial ablation devices, the Symphion Tissue Removal System, and the Resectr Tissue Resection Device, a handheld surgical instrument to enable the hysteroscopic removal and diagnosis of endometrial polyps. The company was incorporated in 2008 and is headquartered in Santa Clara, CA.
Zen Score
–
Industry Average (28)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how UTRS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
UTRS is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
UTRS is good value based on its book value relative to its share price (1.45x), compared to the US Health Information Services industry average (3.51x)
P/B vs Industry Valuation
UTRS is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more UTRS due diligence checks available for Premium users.
Be the first to know about important UTRS news, forecast changes, insider trades & much more!
UTRS News
Valuation
UTRS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.3x
Industry
6.73x
Market
53.21x
UTRS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.45x
Industry
3.51x
UTRS is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
UTRS's financial health
Profit margin
Revenue
$12.5M
Net Income
-$11.3M
Profit Margin
-90.5%
UTRS's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
UTRS's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$85.2M
Liabilities
$51.1M
Debt to equity
1.5
UTRS's short-term assets ($54.11M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
UTRS's short-term assets ($54.11M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
UTRS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$8.4M
Investing
-$75.0k
Financing
$26.8M
UTRS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
UTRS vs Health Information Service Stocks
Minerva Surgical Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.